How India Exports Methylprednisolone to the World

In the United States, methylprednisolone is subject to rigorous regulatory oversight by the Food and Drug Administration (FDA). The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for methylprednisolone, indicating a competitive generic market. Notably, in October 2024, the FDA issued Import Alert 66-66, targeting Active Pharmaceutical Ingredients (APIs) that appear misbranded under section 502(f)(1) due to non-compliance with labeling exemptions specified in 21 CFR 201.122. This alert underscores the necessity for exporters to adhere strictly to FDA labeling requirements to avoid detention without physical examination.

Given that 70% of India's methylprednisolone exports are destined for the U.S., it is imperative for the 355 active Indian exporters to ensure compliance with FDA regulations to maintain market access.

In the European Union (EU) and the United Kingdom (UK), methylprednisolone is regulated by the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. Marketing authorization holders must comply with EU Good Manufacturing Practice (GMP) standards to ensure product quality and safety. In August 2024, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to the product information for methylprednisolone, highlighting the risk of Thyrotoxic Periodic Paralysis. This underscores the importance of continuous pharmacovigilance and adherence to updated regulatory guidelines. (ema.europa.eu)

Methylprednisolone is included in the World Health Organization's (WHO) Model List of Essential Medicines, reflecting its critical role in healthcare systems worldwide. The drug is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality parameters across different regions.

In India, methylprednisolone is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing to ensure affordability. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

Methylprednisolone is a well-established pharmaceutical compound with expired patents, allowing for generic competition. This has led to a diversified market with multiple manufacturers producing the drug, contributing to its widespread availability and competitive pricing.

In October 2024, the FDA issued Import Alert 66-66, emphasizing the need for compliance with labeling requirements for APIs, including methylprednisolone.

In August 2024, the EMA's PRAC recommended updates to the product information for methylprednisolone, highlighting the risk of Thyrotoxic Periodic Paralysis. (ema.europa.eu)

In March 2018, Sagent Pharmaceuticals issued a voluntary nationwide recall of methylprednisolone sodium succinate for injection due to high out-of-specification impurity results, underscoring the importance of stringent quality control measures.

These developments highlight the dynamic regulatory landscape surrounding methylprednisolone, necessitating continuous monitoring and compliance by manufacturers and exporters to ensure market access and patient safety.

Methylprednisolone, a corticosteroid widely used for its anti-inflammatory properties, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where 41% of KSMs used in U.S.-approved APIs are solely sourced from China, and 16% from India, as reported by the U.S. Pharmacopeia in October 2025.

Recent geopolitical tensions and regulatory actions have exacerbated this vulnerability. In March 2026, conflicts in the Middle East disrupted critical shipping routes, including the Strait of Hormuz, leading to significant delays and increased costs in the transportation of pharmaceutical ingredients. Additionally, China's stringent environmental regulations have led to the shutdown of several chemical manufacturing plants, causing supply disruptions and price escalations for essential KSMs.

Our proprietary data indicates that the top five Indian exporters of Methylprednisolone account for 65.5% of total exports, with PAR Formulations Private Limited alone contributing 28.2%. This high supplier concentration poses a significant risk, as any operational or regulatory issues affecting these key players could disrupt the global supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API production and reduce reliance on imports. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and 6-APA, essential for antibiotic production. While these initiatives are steps toward self-reliance, their impact on reducing supplier concentration in the Methylprednisolone market remains to be seen.

The ongoing conflict in the Middle East, particularly the closure of the Strait of Hormuz in March 2026, has severely disrupted global shipping routes. Major maritime carriers have suspended transits through this critical passage, leading to delays and increased transportation costs for pharmaceutical products, including Methylprednisolone.

Furthermore, escalating U.S.-China tensions have raised concerns about the stability of the pharmaceutical supply chain. The U.S. Food and Drug Administration (FDA) has highlighted the risks associated with heavy reliance on foreign-sourced APIs and KSMs, emphasizing the need for diversified sourcing strategies to prevent potential shortages.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for APIs and KSMs.

• Enhance Domestic Production: Invest in local manufacturing capabilities for critical pharmaceutical ingredients to decrease reliance on imports.

• Strengthen Supply Chain Resilience: Develop contingency plans, including alternative shipping routes and inventory buffers, to mitigate disruptions caused by geopolitical events.

• Monitor Regulatory Changes: Stay informed about international regulatory developments that may impact the availability and cost of raw materials.

• Collaborate with Regulatory Bodies: Work closely with agencies like the FDA and EMA to ensure compliance and anticipate potential supply chain challenges.

RISK_LEVEL: HIGH